Multidimensional Impact of Telemonitoring in Heart Failure (IMPACT-HF) (IMPACT-HF)
Heart Failure
About this trial
This is an interventional prevention trial for Heart Failure
Eligibility Criteria
Inclusion Criteria: Diagnosis of HF according to the 2021 guidelines of the European Society of Cardiology criteria for ≥3 months. Admitted for decompensation of chronic HF. Admitted for HF decompensation ≥30 days and ≤6 months. HF decompensation in ≥30 days and ≤6 months but discharged directly from the emergency department or managed on an outpatient basis, but requiring intravenous diuretic administration in an ambulatory basis, or >50% increase in loop diuretic dose. With previous optimized prognostic medical treatment. Under treatment with loop diuretic drugs. New York Heart Association functional class II, III or IV. Exclusion Criteria: Inclusion in other intervention studies. Hemodynamic instability. Acute myocardial infarction, acute pulmonary thromboembolism or stroke in the previous 40 days. Uncontrolled arrhythmias On waiting list for transplantation (any organ) or other cardiac surgery. Advanced mechanical circulatory support. Chronic renal disease on hemodialysis. Life expectancy less than 1 year. Moderate-severe cognitive impairment. Manifest inability to use a technological system. Institutionalized. Limiting psychiatric pathology.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Experimental
No Intervention
Telemonitoring group
Control gropu
Follow-up group by telematic consultations and non-invasive daily telemonitoring of weight, blood pressure, heart rate, peripheral oxygen saturation and electrocardiogram.
Usual care follow-up group